Eli Lilly Management

Management criteria checks 2/4

Eli Lilly's CEO is Dave Ricks, appointed in Jan 2017, has a tenure of 7.25 years. total yearly compensation is $26.57M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth €469.85M. The average tenure of the management team and the board of directors is 5.8 years and 9.4 years respectively.

Key information

Dave Ricks

Chief executive officer

US$26.6m

Total compensation

CEO salary percentage	6.1%
CEO tenure	7.3yrs
CEO ownership	0.08%
Management average tenure	5.8yrs
Board average tenure	9.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dave Ricks's remuneration changed compared to Eli Lilly's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

Compensation vs Market: Dave's total compensation ($USD26.57M) is above average for companies of similar size in the German market ($USD5.57M).

Compensation vs Earnings: Dave's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Dave Ricks (55 yo)

7.3yrs

Tenure

US$26,565,732

Compensation

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Ricks	Chairman	7.3yrs	US$26.57m	0.076% $ 469.9m
Anat Ashkenazi	Executive VP & CFO	3.2yrs	US$7.60m	0.0047% $ 29.1m
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	5.8yrs	US$11.85m	0.022% $ 132.5m
Anat Hakim	Executive VP	4.2yrs	US$7.01m	0.0034% $ 20.8m
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 14.0m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	11.4yrs	no data	0.0011% $ 6.5m
Diogo Rau	EVP & Chief Information and Digital Officer	2.9yrs	US$5.10m	0.00087% $ 5.4m
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	2.8yrs	no data	0.00088% $ 5.4m
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.3yrs	no data	0.00083% $ 5.1m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.3yrs	US$5.38m	no data
W. Moody	SVP of Global Active Pharmaceutical Ingredient	7.7yrs	no data	no data
Johna Norton	Executive Vice President of Global Quality	7yrs	no data	0.0039% $ 23.8m

5.8yrs

Average Tenure

52.5yo

Average Age

Experienced Management: LLY's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Ricks	Chairman	7.3yrs	US$26.57m	0.076% $ 469.9m
Gabrielle Greene-Sulzberger	Independent Director	3.3yrs	US$335.50k	0.00024% $ 1.5m
Sidney Taurel	Chairman Emeritus	15.3yrs	US$13.06m	no data
Jon Erik Fyrwald	Independent Director	18.4yrs	US$344.88k	0.000010% $ 61.6k
Ralph Alvarez	Independent Director	15yrs	US$336.00k	0.000080% $ 492.7k
William Kaelin	Independent Director	11.8yrs	US$349.15k	no data
Juan Luciano	Lead Independent Director	8.2yrs	US$373.00k	0.0017% $ 10.7m
Katherine Baicker	Independent Director	12.3yrs	US$336.00k	no data
Jamere Jackson	Independent Director	7.5yrs	US$345.00k	no data
Marschall Runge	Independent Director	10.6yrs	US$319.00k	0.000020% $ 123.2k
Karen Walker	Independent Director	5.3yrs	US$359.00k	no data
Kimberly Johnson	Independent Director	3.2yrs	US$316.00k	0.00029% $ 1.8m

9.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: LLY's board of directors are considered experienced (9.4 years average tenure).

Eli Lilly Management

Management criteria checks 2/4

Key information

Recent management updates

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Insufficient new directors

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Recent updates

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal

Now 21% undervalued

SEIU Benefit Plans Master Trust Files a Notice of Exempt Solicitation to Eli Lilly and Company

Eli Lilly and Company Announces Results from A First-Of-Its-Kind Study of Lebrikizumab

Now 21% undervalued

Eli Lilly and Company to Present Donanemab in Early Symptomatic Alzheimer's Disease

Full year 2023 earnings released: EPS: US$5.82 (vs US$6.93 in FY 2022)

Now 22% undervalued

Now 21% undervalued

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Full year 2023 earnings released: EPS: US$5.80 (vs US$6.93 in FY 2022)

Upcoming dividend of US$1.30 per share at 0.7% yield

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Insufficient new directors

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Eli Lilly and Company to Report Q4, 2023 Results on Feb 06, 2024

Eli Lilly and Company Launches End-To-End Digital Healthcare Experience Through LillyDirect

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

Eli Lilly and Company Announces Updated Clinical Data from the International Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eli Lilly and Company Declares Dividend for the First Quarter of 2024, Payable on March 8, 2024

Eli Lilly and Company Announces Availability of Zepbound (Tirzepatide) Injection

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Jaypirca (Pirtobrutinib) for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma

U.S. Food and Drug Administration Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Upcoming dividend of US$1.13 per share at 0.8% yield

Eli Lilly and Company Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.064 loss per share (vs US$1.61 profit in 3Q 2022)

Eli Lilly and Company Announces FDA Approval for Omvoh (Mirikizumab-Mrkz) Infusion (300 mg/15 mL)/Injection (100 mg/mL)

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

Eli Lilly and Company to Report Q3, 2023 Results on Nov 02, 2023

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Eli Lilly and Company Announces Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

Boehringer Ingelheim and Eli Lilly and Company Announce US FDA Approves Jardiance for Treatment of Adults with Chronic Kidney Disease

Eli Lilly and Company Announces Topline Results from the Libretto-531 Study Evaluating Retevmo

Eli Lilly and Company (NYSE:LLY) acquired Versanis Bio, Inc. from Medicxi Ventures (UK) LLP and others.

Eli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders.

Eli Lilly and Company Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$1.95 (vs US$1.06 in 2Q 2022)

Upcoming dividend of US$1.13 per share at 1.0% yield

Eli Lilly and Company Announces Topline Results from the Libretto-431 Study Evaluating Retevmo

Eli Lilly and Company Announces Results of Two Phase 3 Tirzepatide Studies in Adults with Obesity or Overweight with Weight-Related Comorbidities, Excluding Type 2 Diabetes

Eli Lilly and Company to Report Q2, 2023 Results on Aug 08, 2023

Eli Lilly and Company Presents Full Results from the Phase 3 Trial of Donanemab

Eli Lilly and Company (NYSE:LLY) enter into a definitive agreement to acquire Versanis Bio, Inc. from Medicxi Ventures (UK) LLP and others for approximately $1.925 billion.

Eli Lilly and Company Announces New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Eli Lilly and Company (NYSE:LLY) acquired unknown minority stake in Eli Lilly and Company (NYSE:LLY) from Heidelberg Pharma GmbH.

Eli Lilly and Company Declares Third-Quarter 2023 Dividend, Payable on September 8, 2023

Eli Lilly and Company(NYSE:LLY) dropped from Russell Top 200 Value Index

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion.

Eli Lilly and Company Announces First-Of-Its-Kind Head-To-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Attorneys At Hagens Berman and Carella Byrne Cecchi Olstein Brody & Agnello Announces Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit

Eli Lilly and Company Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis

Eli Lilly and Company Announces Positive Results of the Trailblazer-Alz 2 Phase 3 Study

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age